Gyre Therapeutics (GYRE) Non-Current Deferred Tax Liability (2023 - 2025)
Gyre Therapeutics (GYRE) has disclosed Non-Current Deferred Tax Liability for 3 consecutive years, with $9.6 million as the latest value for Q4 2025.
- Quarterly Non-Current Deferred Tax Liability rose 15.66% to $9.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.6 million through Dec 2025, up 15.66% year-over-year, with the annual reading at $9.6 million for FY2025, 15.66% up from the prior year.
- Non-Current Deferred Tax Liability for Q4 2025 was $9.6 million at Gyre Therapeutics, up from $8.3 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $9.6 million in Q4 2025, with the low at $2.5 million in Q4 2023.
- Average Non-Current Deferred Tax Liability over 3 years is $6.8 million, with a median of $8.3 million recorded in 2024.
- The sharpest move saw Non-Current Deferred Tax Liability skyrocketed 232.0% in 2024, then grew 15.66% in 2025.
- Over 3 years, Non-Current Deferred Tax Liability stood at $2.5 million in 2023, then surged by 232.0% to $8.3 million in 2024, then rose by 15.66% to $9.6 million in 2025.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at $9.6 million, $8.3 million, and $2.5 million for Q4 2025, Q4 2024, and Q4 2023 respectively.